Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529
Abstract Background Since nearly half of all pregnancies in the US and worldwide are unintended, there is a critical need for additional contraceptive options for men and women. After a hiatus in non-hormonal male contraceptive development of about half a century, the new chemical entity YCT-529 – a...
Saved in:
| Main Authors: | Nadja Mannowetz, Stewart W. McCallum, Sharan Sidhu, Karen H. Mena, Eric P. Ruby, Ramiro Castro-Santamaria, Emily Dodds, Dennis Henderson, Gareth Whitaker, Heather Wright, Sarah Beaudoin, Akash Bakshi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-025-01004-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting the retinoid signaling pathway with YCT-529 for effective and reversible oral contraception in mice and primates
by: Nadja Mannowetz, et al.
Published: (2025-03-01) -
Sentinel lymph node biopsy in patients with breast cancer ycT4N0M0 after neoadjuvant drug therapy
by: M. B. Kurbanova, et al.
Published: (2024-05-01) -
ANÁLISE CRÍTICA DO TEMA 529 DO SUPREMO TRIBUNAL FEDERAL
by: Juliana de Almeida Salvador Fiorilo, et al.
Published: (2025-07-01) -
Pharmacokinetics, Pharmacodynamics and Bioavailability of ACM‐001.1 (S‐Pindolol Benzoate) in Healthy Volunteers
by: Frank Misselwitz, et al.
Published: (2025-02-01) -
Lack of Clinically Meaningful Effect of Cariprazine on the Pharmacokinetics of a Combined Oral Contraceptive
by: Márta Erzsébet Rosa, et al.
Published: (2024-12-01)